Weight Management Lab Testing: How At-Home Kits Support Eligibility and Outcomes

About 40% of U.S. adults have obesity, according to the latest CDC national survey data. That number usually shows up right before a pitch for some weight loss product, and we'd rather start somewhere else.

Weight tells you something about a person's health, though the American Heart Association has pointed out that BMI alone is a limited measure of cardiometabolic risk. For some people, losing weight is a real part of managing blood sugar, blood pressure, or heart health, and it's a goal they've set with their clinician. For plenty of others, it isn't the priority.

In this piece we plan to examine that first group and the programs built to serve them, from digital health companies running weight management programs to health plans looking to support high-risk members. Both need answers a scale can't give: is there a medical reason behind the weight gain, does this person qualify for a given treatment, is the program improving anything beyond the number on the scale?

Lab testing can answer those questions, and at-home collection makes it practical to get those answers at the start of a program and again months later.

The lab panels that matter in weight management

There isn't one "weight loss blood test" that covers everything, so most programs rely on a small set of panels that show what might be driving weight change and how the body is responding to it.

‍‍

Thyroid testing usually comes first, since the NIH lists weight gain as a common symptom of hypothyroidism, a condition that affects nearly 5 in 100 Americans ages 12 and older. The European Society of Endocrinology's clinical guideline goes further and recommends that all patients with obesity be tested for thyroid function, starting with TSH. Results aren't always clear-cut, though. The same guideline notes that TSH tends to run a little higher in people with obesity, often as an adaptive response, and it advises against treating a mildly elevated TSH just to bring weight down. That's why every result should go through a clinician who can decide what it means for that person. Depending on symptoms, clinicians may look at other hormones too.

HbA1c is one of the easier tests to do at home, and the CDC notes you don't need to fast before an A1C test. The ranges are simple, too: below 5.7% is normal, 5.7% to 6.4% is prediabetes, and 6.5% or above indicates diabetes.

Lipid and kidney panels fill in the rest of the picture by showing where someone's heart and kidney health stand at the start, which matters both for safety and for measuring change later.

Testing programs can target one, or all of these measures. You can learn more about our thyroid panel and the important biomarkers to consider in our blog At-Home Testing: What Health Plans Should Know About Thyroid, Testosterone & Cortisol Panels.

How lab results determine eligibility

Many weight management interventions have entry criteria, and a lot of those criteria come down to lab values. GLP-1 medications are the most visible example right now.

Under the Medicare GLP-1 Bridge, which began July 1, 2026, Medicare Part D enrollees can qualify for covered GLP-1s for weight reduction if they meet one of three sets of criteria. According to CMS guidance for prescribers, those are:

• A BMI of 35 or higher
• A BMI of 30 or higher plus heart failure with preserved ejection fraction, uncontrolled hypertension, or stage 3a or higher chronic kidney disease
• A BMI of 27 or higher plus prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease

Two of those qualifying conditions, prediabetes and chronic kidney disease, are typically identified through lab work. And the same A1c result can send someone down a different path entirely. CMS directs people with type 2 diabetes to their Part D plan rather than the Bridge, so an A1c of 6.5% versus 6.2% can change how a request gets routed.

Medication is only one route, though, and someone whose A1c lands in the prediabetes range may be a good fit for a structured lifestyle program instead, or alongside medication. The CDC reports that people with prediabetes in its National Diabetes Prevention Program lowered their risk of type 2 diabetes by 58%, and by 71% for people over 60. Someone with an abnormal thyroid result may need clinical follow-up before any weight program makes sense.

For health plans, this mostly comes down to stratification: lab data helps identify which members carry the most cardiometabolic risk and which intervention fits each of them. Digital health companies tend to be thinking about safety and enrollment, and knowing someone's numbers up front means the right people get into the right program.

Proving a program works

Pounds lost is the easiest outcome to report. It's also the one buyers trust least on its own. A health plan deciding whether to keep funding a weight management partner wants to know if members' clinical risk went down, and that takes biomarker data.

Programs have solid research to benchmark against, including an analysis of more than 5,000 adults with type 2 diabetes from the Look AHEAD trial. In that study, people who lost 5% to under 10% of their body weight were significantly more likely to improve their cardiovascular risk factors after one year than people whose weight stayed the same. They were about 3.5 times as likely to drop their A1c by half a percentage point. They were also more likely to see triglycerides fall by 40 mg/dL and HDL rise by 5 mg/dL.

Those are the kinds of changes a program can show, as long as it has a baseline. In practice that looks like:

1. A full panel at enrollment, before any intervention starts
2. Repeat testing at set intervals, often every three to six months
3. Reporting that ties biomarker changes to the program, at the individual and population level

Repeat testing is useful after the active phase ends, too, because plenty of people stop GLP-1s at some point and managing what happens after that depends on knowing whether A1c and lipids are holding steady. Some programs already build regular at-home biomarker testing into the member experience for exactly this reason.

Weight, heart disease, and diabetes: where it connects for health plans

Excess weight rarely travels alone. The AHA links obesity to higher blood pressure, abnormal blood lipids, and elevated blood glucose, along with inflammation that drives atherosclerosis. So the members a plan might reach through a weight management effort often overlap with the members it's already trying to reach for diabetes, kidney, and blood pressure care.

You can see that overlap in HEDIS, where members with diabetes count toward Glycemic Status Assessment (GSD), which depends on a current A1c. Many of the same members fall under Kidney Health Evaluation (KED), which requires both an eGFR and a uACR. A program that's already sending a kit for metabolic testing can be designed to support those measures too, with one outreach effort instead of several.

For Medicare Advantage plans, the practical upside is being able to support members who've chosen to work on their weight while also closing care gaps that affect quality reporting.

Why at-home collection makes this work

None of this works unless people actually get tested, usually more than once, and that's hard to pull off when it means taking time off work, finding a lab, and sitting in a waiting room every few months.

At-home kits remove most of that friction because the kit shows up with instructions, the person collects a sample on their own schedule, and a prepaid label gets it back to the lab. And, for tests like A1c, there's no fasting to plan around. Results go to a clinician for review and then back to the member or patient, with follow-up for anything abnormal.

Getting the kit used still takes good outreach. Members who receive Ash's multi-channel outreach complete testing 2.4× more often than with single-channel methods. For a weight management program, more completed baselines and follow-ups means more people with data showing whether the program is helping them.

Ash offers 100+ biomarkers available in all 50 states, including a GLP-1 Suitability Panel built to help identify people who may be eligible for weight loss medication. 

Build lab data into your weight management program

If weight management is part of your members' or patients' care, testing should be part of the program from day one. It tells you who qualifies and helps keep people safe. It also gives you the outcome data to show the program is worth funding.

Ash sees this firsthand as the lab testing partner behind dozens of GLP-1 programs. That includes Noom's Proactive Health Microdose GLP-1Rx Program, where participants test 17 biomarkers at home every 16 weeks, and we've shipped tens of thousands of kits for the program since it launched at the end of 2025. 

Ash runs the whole testing workflow under your brand, from outreach and kit fulfillment to lab processing, clinician review, and reporting. See how it works for digital health companies and health plans, or take a look at our platform.

Ready to add at-home testing to your weight management program? Contact Ash to talk through what your program needs.